Literature DB >> 27731525

Animal models of COPD: What do they tell us?

Bernadette Jones1, Chantal Donovan1, Gang Liu1, Henry M Gomez1, Vrushali Chimankar1, Celeste L Harrison1, Cornelis H Wiegman2, Ian M Adcock2, Darryl A Knight1, Jeremy A Hirota3, Philip M Hansbro1.   

Abstract

COPD is a major cause of global mortality and morbidity but current treatments are poorly effective. This is because the underlying mechanisms that drive the development and progression of COPD are incompletely understood. Animal models of disease provide a valuable, ethically and economically viable experimental platform to examine these mechanisms and identify biomarkers that may be therapeutic targets that would facilitate the development of improved standard of care. Here, we review the different established animal models of COPD and the various aspects of disease pathophysiology that have been successfully recapitulated in these models including chronic lung inflammation, airway remodelling, emphysema and impaired lung function. Furthermore, some of the mechanistic features, and thus biomarkers and therapeutic targets of COPD identified in animal models are outlined. Some of the existing therapies that suppress some disease symptoms that were identified in animal models and are progressing towards therapeutic development have been outlined. Further studies of representative animal models of human COPD have the strong potential to identify new and effective therapeutic approaches for COPD.
© 2016 Asian Pacific Society of Respirology.

Entities:  

Keywords:  animal models; chronic obstructive pulmonary disease; disease mechanisms; therapeutic targets; therapies

Mesh:

Year:  2016        PMID: 27731525     DOI: 10.1111/resp.12908

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  40 in total

Review 1.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.

Authors:  Mathew Suji Eapen; Philip M Hansbro; Anna-Karin Larsson-Callerfelt; Mohit K Jolly; Stephen Myers; Pawan Sharma; Bernadette Jones; Md Atiqur Rahman; James Markos; Collin Chia; Josie Larby; Greg Haug; Ashutosh Hardikar; Heinrich C Weber; George Mabeza; Vinicius Cavalheri; Yet H Khor; Christine F McDonald; Sukhwinder Singh Sohal
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

2.  Understanding the Relevance of the Mouse Cigarette Smoke Model of COPD: Peering through the Smoke.

Authors:  R William Vandivier; Moumita Ghosh
Journal:  Am J Respir Cell Mol Biol       Date:  2017-07       Impact factor: 6.914

3.  Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways.

Authors:  Kent Miner; Katja Labitzke; Benxian Liu; Paul Wang; Kathryn Henckels; Kevin Gaida; Robin Elliott; Jian Jeffrey Chen; Longbin Liu; Anh Leith; Esther Trueblood; Kelly Hensley; Xing-Zhong Xia; Oliver Homann; Brian Bennett; Mike Fiorino; John Whoriskey; Gang Yu; Sabine Escobar; Min Wong; Teresa L Born; Alison Budelsky; Mike Comeau; Dirk Smith; Jonathan Phillips; James A Johnston; Joseph G McGivern; Kerstin Weikl; David Powers; Karl Kunzelmann; Deanna Mohn; Andreas Hochheimer; John K Sullivan
Journal:  Front Pharmacol       Date:  2019-02-14       Impact factor: 5.810

4.  IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis.

Authors:  Malcolm R Starkey; Maximilian W Plank; Paolo Casolari; Alberto Papi; Stelios Pavlidis; Yike Guo; Guy J M Cameron; Tatt Jhong Haw; Anthony Tam; Ma'en Obiedat; Chantal Donovan; Nicole G Hansbro; Duc H Nguyen; Prema Mono Nair; Richard Y Kim; Jay C Horvat; Gerard E Kaiko; Scott K Durum; Peter A Wark; Don D Sin; Gaetano Caramori; Ian M Adcock; Paul S Foster; Philip M Hansbro
Journal:  Eur Respir J       Date:  2019-07-18       Impact factor: 16.671

Review 5.  Ventilation/Perfusion Matching: Of Myths, Mice, and Men.

Authors:  Alys R Clark; Kelly S Burrowes; Merryn H Tawhai
Journal:  Physiology (Bethesda)       Date:  2019-11-01

Review 6.  IL-33 in Chronic Respiratory Disease: From Preclinical to Clinical Studies.

Authors:  Chantal Donovan; Philip M Hansbro
Journal:  ACS Pharmacol Transl Sci       Date:  2019-12-20

Review 7.  Applications and Approaches for Three-Dimensional Precision-Cut Lung Slices. Disease Modeling and Drug Discovery.

Authors:  Hani N Alsafadi; Franziska E Uhl; Ricardo H Pineda; Kolene E Bailey; Mauricio Rojas; Darcy E Wagner; Melanie Königshoff
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

Review 8.  COPD and the gut-lung axis: the therapeutic potential of fibre.

Authors:  Annalicia Vaughan; Zoe A Frazer; Philip M Hansbro; Ian A Yang
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

9.  Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort.

Authors:  William Z Zhang; Michelle C Rice; Katherine L Hoffman; Clara Oromendia; Igor Z Barjaktarevic; J Michael Wells; Annette T Hastie; Wassim W Labaki; Christopher B Cooper; Alejandro P Comellas; Gerard J Criner; Jerry A Krishnan; Robert Paine; Nadia N Hansel; Russell P Bowler; R Graham Barr; Stephen P Peters; Prescott G Woodruff; Jeffrey L Curtis; Meilan K Han; Karla V Ballman; Fernando J Martinez; Augustine Mk Choi; Kiichi Nakahira; Suzanne M Cloonan; Mary E Choi
Journal:  JCI Insight       Date:  2020-02-13

Review 10.  Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance.

Authors:  Lloyd Tanner; Andrew Bruce Single
Journal:  J Innate Immun       Date:  2019-09-17       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.